PharmaTutor
12 March 2014

Now blood test can predict Alzheimer’s and Mild Dementia

A blood test that can predict with 90 percent accuracy if a healthy person will develop mild cognitive impairment (MCI) or Alzheimer’s disease (AD) within three years has been discovered and validated by researchers at Georgetown and six other institutions. They discovered and validated 10 lipid biomarkers out of which 2 are strongly associated with neuropathology of AD.

11 March 2014
Recruitment of Associate Professor in Mizoram University

Mizoram University is a Central University being set up on modern standards with excellent academic infrastructure and research facilities including a Central Analytical and Preparatory Facility consisting of sophisticated equipments. Mizoram is one of the most peaceful states in the country despite being located in the NER. Aizawl is connected by Air from Kolkata and Guwahati (daily flights). Nearest railhead is at Silchar (180 km). The climate is mild both in summer and winter.

Post: Associate Professor

11 March 2014
Walk in interview for Junior Research Fellow @ National Institute of Nutrition

Eligible candidates are invited to attend a WALK-IN-INTERVIEW on the following date at 9.30 A.M. sharp for the following position on the ad hoc research project entitled “Intra-cellular mechanisms of naturally available neuro-protective compounds in mitigating the combined toxicity generated by the lead in combination with amyloid peptides in Human Brain cells”. The essential qualification, experience, consolidated Fellowship and service tenure are as under: The project is sanctioned and funded by ICMR.

Post: Junior Research Fellow- One

11 March 2014
Invitation to join as Senior Research Fellow, Junior Research Fellow @ NATIONAL INSTITUTE OF PATHOLOGY - ICMR

Applications are invited for one Senior Research Fellow (SRF) in ICMR funded project titled “Study on Micro RNA Signatures Associated with Breast Cancer Stem like Cells (CSCs) and their role in Drug Response”.

Post: Senior Research Fellow, Junior Research Fellow

11 March 2014
Job for Bachelors and Masters degree in Life Sciences as Marketing Specialist in Life Technologies

We’re a global biotechnology company dedicated to improving the human condition. Our industry-leading brands are found in nearly every life sciences lab in the world, including innovative instrument systems under the Applied Biosystems and Ion Torrent names. We’re also responsible for a broad range of reagents with our Invitrogen, GIBCO, Ambion, Molecular Probes and Taqman products. With approximately 3,900 patents and exclusive licenses, we’re home to one of the largest intellectual property estates in the life sciences industry

Post: Marketing Specialist

11 March 2014
IN SILICO DESIGN AND COMPUTATIONAL STUDY OF NOVEL 1, 3, 4-THIADIAZOLE DERIVATIVES AS POTENTIAL AFFINITY WITH NA/H EXCHANGER RECEPTOR FOR ANTICONVULSANT ACTIVITY

{ DOWNLOAD AS PDF }

ABOUT AUTHORS:
Vinit Raj*, Amit Rai, Jitendra Kumar Rawat
Department of Pharmaceutical Sciences,
Babasaheb Bhimrao Ambedkar University (A Central University),
Vidya Vihar, Raebreli Road, Lucknow-226025 (U.P.), India
raj.vinit24@gmail.com

ABSTRACT
A series of novel 1, 3, 4-thiadiazole derivatives were designed keeping in view the structural requirement of pharmacophore and Quantitative structure activity relationship (QSAR) and evaluated in silico anticonvulsant activity. Docking procedures allow virtually screening a database of compounds and predict the strongest binder based on various scoring functions. In the docking study, the most active compounds of the series were, VR 2, VR 3 and VR 4 exhibited good binding properties. Result reveals that the protein-ligand interaction energy of derivatives VR 2, VR 3 and VR 4 were -7.08 kcal/mol, -6.64 kcal/mol and -7.42 kcal/mol respectively, which is slightly higher than the standard anticonvulsant phenytoin drug as -6.03 kcal/mol, so that the derivatives have satisfactory affinity with established convulsant receptor namely Na/H exchanger. A computational study was also carried out including prediction of pharmacokinetic properties, toxicity and bioactivity studies. The percentage of absorption (%ABS) was calculated and observed that all titled compounds exhibited a better %ABS ranging 92.66, 85.81, 90.07 and 86.98, respectively and compared than standard Phenytoin drug as %ABS 88.92. Although VR 1 had slightly lesser protein affinity, its other pharmacological parameters were same like other screened compounds. The above observation suggested that these compounds would serve as better lead compound for anticonvulsant screening for future drug design perspective.

11 March 2014
New Class of Antibiotics found for treatment of Superbug - MRSA and other drug-resistant bacterias

A team of University of Notre Dame researchers led by Mayland Chang and Shahriar Mobashery have discovered a new class of antibiotics to fight bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and other drug-resistant bacteria that threaten public health.

11 March 2014
Synthetic Biologics announces issuance of US Patent for the use of Oral Estriol -Trimesta™ for treatment of Multiple Sclerosis & other Autoimmune Diseases

Synthetic Biologics, Inc., a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA).

11 March 2014
Risk of dying is revealed among healthy people !

Novel biological markers have discovered by researchers from Finland and Estonia  that are strongly indicative of risk of dying from any disease within the near future. Blood samples from over 17000 generally healthy people were screened for more than a hundred different biomolecules. The health status of these study volunteers was followed for several years. The researchers looked for measures in the blood that could reflect who had died within the following 5 years after the blood sample was taken. In a study published in PLOS Medicine, they describe identification of four such biomarkers of death.

10 March 2014
Work as Technical Manager in Colorcon | Ph.D. in Pharmaceutical Sciences with exp

Colorcon is a world leader in the development, supply and technical support of formulated coatings and other excipients for the pharmaceutical and dietary/food/nutritional supplement industries. Our best-in-class products and pharmaceutical technologies are complemented by our value-added services which support all phases of solid oral dose design and development.

Post: Technical Manager